Inion has received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) today for its biogradable graft containment systems for spinal fusion problems.
Inion has been focusing on creating and mainstreaming novel biodegradable medical implants, which gives prominent clinical benefits over classical metal materials, mainly in that they slowly and completely degrade over time into carbon dioxide and water, which are absorbed into the body.
“The US marketing clearance for our biodegradable spine products is great news” states CEO Chris Lee.
“We are already seeing an increased uptake of this important product line in Europe where awareness and acceptance of the clinical benefits of biogradable medical implants is rapidly growing among surgeons, who are adopting this technology into their practice.
“Our aim now is to push these new biodegradable products aggressively into the US spine market where we believe it will make an attractive alternative to traditional metal plates and a strong driver of value for the Company.”
For more information, go online to Inion